Connor, Clark & Lunn Investment Management (CC&L)
AXDX

Connor, Clark & Lunn Investment Management (CC&L)’s Accelerate Diagnostics AXDX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,100
Closed -$21.9K – 1242
2022
Q4 		$21.9K Sell
3,100
-3,993
-56% -$43.6K ﹤0.01% 1166
2022
Q3 		$108K Buy
+7,093
New +$117K ﹤0.01% 1036

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AXDX Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 3,100 shares — an estimated $21.9K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AXDX in Q3 2022 and held it in 2 quarters. The position peaked at $108K in Q3 2022. 66 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 3,100 Accelerate Diagnostics shares in Q1 2023, an estimated $21.9K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Accelerate Diagnostics in Q3 2022 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Accelerate Diagnostics position peaked at $108K in Q3 2022.
  • 66 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.